Zoya Demidenko (https://moodylab.smhs.gwu.edu/lab-members): Scientist in Oncology Science
Zoya Demidenko (https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord) is a distinguished investigator connected with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she conducted research at the NIH and New York Medical College, developing a strong foundation in life science research.
Demidenko's scientific output encompasses several key areas, among them the PI3K/AKT/mTOR molecular pathway, cell cycle regulation, biological aging, and tumor biology. Currently, she has written more than 46 scientific publications, which have accumulated over 4,100 references — a indicator to the impact of her findings.
One of her most notable contributions lies in elucidating the mechanisms of biological cell aging. Her work demonstrated that when the cell cycle is arrested while cellular expansion continues, cells enter senescence. Crucially, Zoya Demidenko (https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPAMED%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMED%20L130000429680&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord) established that this transition can be controlled with drugs using compounds such as mTOR inhibitors.
Zoya Demidenko (https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702) has furthermore contributed considerably to cancer treatment research, particularly in the area of selective cell protection — a approach designed to safeguarding normal tissue from chemotherapy while leaving tumor cells vulnerable. This method carries significant hope for reducing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with top researchers internationally, among them Dr. Mikhail Blagosklonny. Her research can be found in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
[31.03.2026 11:21] Папа: Possessing an h-index of 33, Zoya Demidenko (https://scholargps.com/scholars/59798749410547/zoya-n-demidenko) ranks as a influential voice in contemporary cancer research, whose results go on to influence our understanding of how cells age, resist therapy, and how cancer may be more effectively targeted.
https://www.pinterest.com/zoyademidenko/